CO7240369A2 - Ácido 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso - Google Patents

Ácido 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso

Info

Publication number
CO7240369A2
CO7240369A2 CO15007422A CO15007422A CO7240369A2 CO 7240369 A2 CO7240369 A2 CO 7240369A2 CO 15007422 A CO15007422 A CO 15007422A CO 15007422 A CO15007422 A CO 15007422A CO 7240369 A2 CO7240369 A2 CO 7240369A2
Authority
CO
Colombia
Prior art keywords
aminotetrahydroquinolin
novel
carboxylic acid
treatment
prevention
Prior art date
Application number
CO15007422A
Other languages
English (en)
Inventor
Michael Hahn
Markus Follmann
Walter Hubsch
Eva-María Becker-Pelster
Johannes-Peter Stasch
Joerg Keldenich
Hanna Tinel
Frank Wunder
Joachim Mittendorf
Ildiko Terebesi
Dieter Lang
René Martin
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CO7240369A2 publication Critical patent/CO7240369A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

La presente solicitud se refiere a ácidos 5-aminotetrahidroquinolin-2- carboxilicos novedosos, a procedimientos para su preparación, a su uso para el tratamiento y/o la prevención de enfermedades así como a su uso para la preparación de medicamentos para el tratamiento y/o la prevención de enfermedades, especialmente para el tratamiento y/o la prevención de enfermedades cardiovasculares y cardiopulmonares.
CO15007422A 2012-07-20 2015-01-15 Ácido 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso CO7240369A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12177284 2012-07-20
EP13167967 2013-05-16

Publications (1)

Publication Number Publication Date
CO7240369A2 true CO7240369A2 (es) 2015-04-17

Family

ID=48914233

Family Applications (1)

Application Number Title Priority Date Filing Date
CO15007422A CO7240369A2 (es) 2012-07-20 2015-01-15 Ácido 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso

Country Status (41)

Country Link
US (3) US8981104B2 (es)
EP (1) EP2875003B1 (es)
JP (1) JP6251259B2 (es)
KR (1) KR102137517B1 (es)
CN (1) CN104822661B (es)
AR (1) AR091838A1 (es)
AU (1) AU2013292046C1 (es)
BR (1) BR112015001211B1 (es)
CA (1) CA2879369C (es)
CL (1) CL2015000120A1 (es)
CO (1) CO7240369A2 (es)
CR (1) CR20150020A (es)
CY (1) CY1118588T1 (es)
DK (1) DK2875003T3 (es)
DO (1) DOP2015000012A (es)
EA (1) EA028918B9 (es)
EC (1) ECSP15001882A (es)
ES (1) ES2616036T3 (es)
GT (1) GT201500011A (es)
HK (1) HK1209413A1 (es)
HR (1) HRP20170185T1 (es)
HU (1) HUE030540T2 (es)
IL (1) IL236616B (es)
JO (1) JO3343B1 (es)
LT (1) LT2875003T (es)
ME (1) ME02603B (es)
MX (1) MX360863B (es)
MY (1) MY172994A (es)
NZ (1) NZ702977A (es)
PE (1) PE20150350A1 (es)
PH (1) PH12015500106B1 (es)
PL (1) PL2875003T3 (es)
PT (1) PT2875003T (es)
RS (1) RS55651B1 (es)
SG (2) SG11201408421TA (es)
SI (1) SI2875003T1 (es)
TN (1) TN2015000026A1 (es)
TW (1) TWI598338B (es)
UY (1) UY34918A (es)
WO (1) WO2014012934A1 (es)
ZA (1) ZA201409394B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
JP6118965B2 (ja) 2012-04-16 2017-04-26 トーアエイヨー株式会社 ２環性化合物
LT2875003T (lt) * 2012-07-20 2017-02-27 Bayer Pharma Aktiengesellschaft Naujos 5-aminotetrahidrochinolin-2-karboksirūgštys ir jų panaudojimas
CN104703964B (zh) 2012-07-20 2017-04-12 拜耳制药股份公司 取代氨基茚满‑和氨基萘满甲酸及其用途
FR3000065A1 (fr) * 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes
CN107250113B (zh) 2014-10-07 2019-03-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调节蛋白的调节剂的共晶
CN107580495A (zh) 2015-05-06 2018-01-12 拜耳制药股份公司 单独和与PDE5抑制剂组合的sGC刺激剂、sGC活化剂用于治疗伴随系统性硬化症(SSc)的指溃疡(DU)的用途
US11166932B2 (en) 2015-07-23 2021-11-09 Bayer Pharma Aktiengesellschaft Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination with an inhibitor of neutral endopeptidase (NEP inhibitor) and/or an angiotensin AII antagonist and the use thereof
US10682323B2 (en) 2016-07-22 2020-06-16 Toa Eiyo Ltd. Therapeutic agent for glaucoma
US11331308B2 (en) 2016-10-11 2022-05-17 Bayer Pharma Aktiengesellschaft Combination containing sGC activators and mineralocorticoid receptor antagonists
WO2018153899A1 (de) 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit stimulatoren und/oder aktivatoren der löslichen guanylatcyclase (sgc)
BR112020007967A2 (pt) 2017-10-24 2020-10-20 Bayer Aktiengesellschaft imidazopiridina amidas substituídas e uso das mesmas
WO2019081456A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
EP3498298A1 (en) 2017-12-15 2019-06-19 Bayer AG The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi)
CN108218770A (zh) * 2018-02-28 2018-06-29 南京波普生物医药研发有限公司 2-氯-7,8-二氢-6h-喹啉-5-酮的制备方法
US20210052528A1 (en) 2018-04-30 2021-02-25 Bayer Aktiengesellschaft The use of sgc activators and sgc stimulators for the treatment of cognitive impairment
EA202092680A1 (ru) 2018-05-15 2021-04-13 Байер Акциенгезельшафт 1,3-тиазол-2-ил-замещенные бензамиды для лечения заболеваний, ассоциированных с сенситизацией нервных волокон
EP3574905A1 (en) 2018-05-30 2019-12-04 Adverio Pharma GmbH Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group
US10905667B2 (en) 2018-07-24 2021-02-02 Bayer Pharma Aktiengesellschaft Orally administrable modified-release pharmaceutical dosage form
WO2020148379A1 (en) 2019-01-17 2020-07-23 Bayer Aktiengesellschaft Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc)
WO2020164008A1 (en) 2019-02-13 2020-08-20 Bayer Aktiengesellschaft Process for the preparation of porous microparticles
WO2020216669A1 (de) 2019-04-23 2020-10-29 Bayer Aktiengesellschaft Phenylsubstituierte imidazopyridinamide und ihre verwendung
PE20220431A1 (es) 2019-05-07 2022-03-29 Bayer Ag Compuestos inhibidores de la masp y usos de estos
EP3822265A1 (en) 2019-11-15 2021-05-19 Bayer AG Substituted hydantoinamides as adamts7 antagonists
EP3822268A1 (en) 2019-11-15 2021-05-19 Bayer Aktiengesellschaft Substituted hydantoinamides as adamts7 antagonists
EP4153569A1 (de) 2020-05-20 2023-03-29 Bayer Aktiengesellschaft Verfahren zur herstellung von butyl-(5s)-5-({2-[4-(butoxycarbonyl)phenyl]ethyl}[2-(2-{[3-chlor-4'-(trifluormethyl)[biphenyl]-4-yl]methoxy}phenyl)ethyl]amino)-5,6,7,8-tetrahydrochinolin-2-carboxylat
WO2023126436A1 (en) 2021-12-29 2023-07-06 Bayer Aktiengesellschaft Process for preparing (5s)-{[2-(4-carboxyphenyl)ethyl] |2-(2-{|3-chloro-4'-(trifluoromethyl)biphenyl-4- yl]methoxy}phenyl)ethyl]aminol-5,6,7,8-tetrahydroquinoline-2-carboxylic acid and its crystalline forms for use as pharmaceutically active compound
WO2023126437A1 (en) 2021-12-29 2023-07-06 Bayer Aktiengesellschaft Treatment of cardiopulmonary disorders
WO2023126438A1 (en) 2021-12-29 2023-07-06 Bayer Aktiengesellschaft Pharmaceutical dry powder inhalation formulation
WO2023237577A1 (en) 2022-06-09 2023-12-14 Bayer Aktiengesellschaft Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8004002L (sv) 1980-05-29 1981-11-30 Arvidsson Folke Lars Erik Terapeutiskt anvendbara tetralinderivat
IL65501A (en) 1981-05-08 1986-04-29 Astra Laekemedel Ab 1-alkyl-2-aminotetralin derivatives,process for their preparation and pharmaceutical compositions containing them
DE3718317A1 (de) 1986-12-10 1988-06-16 Bayer Ag Substituierte basische 2-aminotetraline
DE3719924A1 (de) 1986-12-22 1988-06-30 Bayer Ag 8-substituierte 2-aminotetraline
DK0476016T3 (da) 1989-05-31 1999-07-05 Upjohn Co CNS-aktive 8-heterocyclyl-2-aminotetralin-derivater
FR2659853A1 (fr) 1990-03-22 1991-09-27 Midy Spa Utilisation de derives 2-aminotetraliniques pour la preparation de medicaments destines a combattre les troubles de la motricite intestinale.
HU225986B1 (en) 1994-01-10 2008-02-28 Teva Pharma Use of 1-aminoindan derivatives for preparing pharmaceutical compns. and 1-aminoindan derivatives
CA2333951C (en) 1998-06-01 2012-02-28 Ortho-Mcneil Pharmaceutical, Inc. Method for treating neurodegenerative disorders
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
GB9827467D0 (en) 1998-12-15 1999-02-10 Zeneca Ltd Chemical compounds
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10109858A1 (de) 2001-03-01 2002-09-05 Bayer Ag Neuartige halogensubstituierte Aminodicarbonsäurederivate
DE10109859A1 (de) 2001-03-01 2002-09-05 Bayer Ag Neuartige Aminodicarbonsäurederivate
DE10109861A1 (de) 2001-03-01 2002-09-05 Bayer Ag Neuartige seitenkettenhalogenierte Aminodicarbonsäurederivate
DE10110750A1 (de) * 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
US20050032873A1 (en) 2003-07-30 2005-02-10 Wyeth 3-Amino chroman and 2-amino tetralin derivatives
GB0318094D0 (en) * 2003-08-01 2003-09-03 Pfizer Ltd Novel combination
JP2008534593A (ja) 2005-03-30 2008-08-28 メルク エンド カムパニー インコーポレーテッド グルカゴン受容体アンタゴニスト化合物、そのような化合物を含む組成物、及びその使用方法
DE102005047946A1 (de) * 2005-10-06 2007-05-03 Bayer Healthcare Ag Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von akuten und chronischen Lungenkrankheiten
DE102005050377A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Heterocyclische Verbindungen und ihre Verwendung
DE102006031175A1 (de) * 2006-07-06 2008-01-10 Bayer Healthcare Ag Wässrige Arzneimittelformulierung von 4-[((4-Carboxybutyl)-(2[(4-phenethyl-benzyl)oxy]-phenethyl)amino)methyl]benzoesäur
WO2009023669A1 (en) 2007-08-13 2009-02-19 Janssen Pharmaceutica N.V. Substituted 5,6,7,8-tetrahydroquinoline derivatives, compositions, and methods of use thereof
KR20100059952A (ko) 2007-09-06 2010-06-04 머크 샤프 앤드 돔 코포레이션 가용성 구아닐레이트 사이클라제 활성제
EP2331498B1 (en) * 2008-08-19 2016-11-09 Janssen Pharmaceutica NV Cold menthol receptor antagonists
DE102010020553A1 (de) 2010-05-14 2011-11-17 Bayer Schering Pharma Aktiengesellschaft Substituierte 8-Alkoxy-2-aminotetralin-Derivate und ihre Verwendung
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EP2687210A1 (de) 2010-06-25 2014-01-22 Bayer Intellectual Property GmbH Verwendung von Stimulatoren und Aktivatoren der löslichen Guanylatzyklase zur Behandlung von Sichelzellanämie und Konservierung von Blutersatzstoffen
BR112013000596A2 (pt) 2010-07-09 2019-09-24 Bayer Intelectual Property Gmbh piridinas e tiazinas fusionadas e seus usos.
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
JP5715713B2 (ja) 2011-03-10 2015-05-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性グアニル酸シクラーゼ活性化因子
JP6118965B2 (ja) * 2012-04-16 2017-04-26 トーアエイヨー株式会社 ２環性化合物
LT2875003T (lt) * 2012-07-20 2017-02-27 Bayer Pharma Aktiengesellschaft Naujos 5-aminotetrahidrochinolin-2-karboksirūgštys ir jų panaudojimas
CN104703964B (zh) 2012-07-20 2017-04-12 拜耳制药股份公司 取代氨基茚满‑和氨基萘满甲酸及其用途

Also Published As

Publication number Publication date
TWI598338B (zh) 2017-09-11
UY34918A (es) 2014-02-28
CY1118588T1 (el) 2017-07-12
ECSP15001882A (es) 2015-09-30
GT201500011A (es) 2017-10-09
JP6251259B2 (ja) 2017-12-20
CA2879369A1 (en) 2014-01-23
CR20150020A (es) 2015-03-06
EA028918B1 (ru) 2018-01-31
JP2015522597A (ja) 2015-08-06
DK2875003T3 (en) 2017-02-20
KR102137517B1 (ko) 2020-07-24
NZ702977A (en) 2017-10-27
RS55651B1 (sr) 2017-06-30
EA028918B9 (ru) 2018-07-31
MX360863B (es) 2018-11-09
IL236616B (en) 2018-05-31
CN104822661A (zh) 2015-08-05
BR112015001211A2 (pt) 2017-07-04
TN2015000026A1 (en) 2016-06-29
PH12015500106A1 (en) 2015-03-02
BR112015001211B1 (pt) 2020-12-15
MX2015000739A (es) 2015-08-10
US10053428B2 (en) 2018-08-21
CN104822661B (zh) 2017-05-31
AU2013292046B2 (en) 2017-12-14
MY172994A (en) 2019-12-18
PL2875003T3 (pl) 2017-05-31
LT2875003T (lt) 2017-02-27
CA2879369C (en) 2020-09-22
ES2616036T3 (es) 2017-06-09
US8981104B2 (en) 2015-03-17
US20140031391A1 (en) 2014-01-30
HK1209413A1 (en) 2016-04-01
WO2014012934A1 (de) 2014-01-23
CL2015000120A1 (es) 2015-06-26
PT2875003T (pt) 2017-02-16
SG10201700454PA (en) 2017-03-30
TW201408643A (zh) 2014-03-01
PH12015500106B1 (en) 2015-03-02
EP2875003A1 (de) 2015-05-27
US20170260139A1 (en) 2017-09-14
ME02603B (me) 2017-06-20
SG11201408421TA (en) 2015-02-27
HRP20170185T1 (hr) 2017-03-24
AU2013292046C1 (en) 2018-03-15
DOP2015000012A (es) 2015-03-15
KR20150036084A (ko) 2015-04-07
JO3343B1 (ar) 2019-03-13
HUE030540T2 (en) 2017-05-29
SI2875003T1 (sl) 2017-03-31
ZA201409394B (en) 2016-07-27
EP2875003B1 (de) 2016-11-16
PE20150350A1 (es) 2015-02-28
US9688636B2 (en) 2017-06-27
AR091838A1 (es) 2015-03-04
EA201590251A1 (ru) 2015-07-30
AU2013292046A1 (en) 2015-02-19
IL236616A0 (en) 2015-02-26
US20150148376A1 (en) 2015-05-28

Similar Documents

Publication Publication Date Title
CO7240369A2 (es) Ácido 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso
UY33776A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
UY32970A (es) Acidos 3-fenilpropionicos sustituidos y su uso
ECSP12012310A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
DOP2013000239A (es) Derivados de ácido 3-fenilpropiónico ramificados y su uso.
UY35115A (es) Imidazo[1,2-a]piridincarboxamidas aminosustituidas y su uso
CR20150370A (es) Compuestos antivirales
ECSP12012125A (es) Ariltriazolonas ligadas a bisarilo y su uso
DOP2014000043A (es) Pirimidinas anilladas sustituidas y uso de las mismas
DOP2014000255A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
EA201491028A8 (ru) Способ получения замещенных 5-фтор-1н-пиразолопиридинов
UY31310A1 (es) Ácidos 6-fenilnicotínicos sustituidos y su uso
UY35745A (es) Derivados sustituidos de fenilalanina
UY35771A (es) Tienouracil-carboxamidas cíclicas y su uso
ES2403549R1 (es) Co-cristales de agomelatina con formadores de co-cristales
CU20130078A7 (es) Ácidos 1-bencicloalquilcarboxílicos sustituidos y su uso
CR20120445A (es) Ariltriazolonas ligadas a bisarilo y su uso
CU24321B1 (es) Derivados de ácidos 5-aminotetrahidroquinolin-2-carboxílicos sustituidos para prevenir y tratar enfermedades cardiovasculares y cardiopulmonares
DOP2011000211A (es) Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hematologicas